Not an actual patient with Fabry disease.

Keep Your Fabry Patients

MOVING FORWARD

Galafold is a 123 mg capsule
Consider how the first and only oral therapy may help
For adults with confirmed Fabry disease and an amenable galactosidase alpha gene (GLA) variant
Download the Galafold Patient Referral Form
Start a Patient

Keep Your Fabry Patients

MOVING FORWARD

Galafold is a 123 mg capsule
Consider how the first and only oral therapy may help
For adults with confirmed Fabry disease and an amenable galactosidase alpha gene (GLA) variant
Download the Galafold Patient Referral Form
Start a Patient
Not an actual patient with Fabry disease.

For adults with confirmed Fabry disease and an amenable galactosidase alpha gene (GLA) variant associated with either the classic* or non-classic phenotype1,2

*
Defined as males with residual peripheral blood mononuclear cell alpha-galactosidase A (alpha-Gal A) <3% of normal and multiorgan system involvement.2
INDICATIONS AND USAGE

Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

INDICATIONS AND USAGE

Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Find out more about Galafold

Help your patients get support with AMICUS ASSIST®
AMICUS ASSIST is a program designed to provide assistance and support to help eligible patients with Fabry disease and an amenable GLA variant obtain access to Galafold.*
Visit
Check if your patient’s GLA variant is amenable to Galafold
Use this search tool to find out whether a specific GLA variant has been listed in the Full Prescribing Information.
Check Now
Learn about an option for genetic testing for Fabry disease
Learn about a no-charge option for genetic testing to help you confirm a diagnosis and determine your patient’s specific GLA variant.
Learn More
*
Patients must be prescribed Galafold for an approved indication to be eligible for support from AMICUS ASSIST.